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etanercept. For the combined ACR & PASI scores, the NNT
ranges were 2.3 to 7.0 for inﬂiximab and 2.9 to 33.3 for etan-
ercept. Using average wholesale price minus 15% (AWP -15%),
the cost per successful outcome based on the ACR score ranged
from $54,235 to $82,435 for inﬂiximab and from $43,000 to
$198,860 for etanercept. For PASI scores, the cost per success-
ful outcome ranged from $30,900 to $53,390 for inﬂiximab and
from $54,860 to $530,280 for etanercept. For the combined
ACR & PASI scores, the cost per successful outcome ranged from
$46,280 to $144,220 for inﬂiximab and from $46,790 to
$530,280 for etanercept. CONLCUSIONS: This Excel based CE
model enables payers to perform CE analyses for anti-TNF
agents used in the treatment of psoriatic arthritis, utilizing plan-
speciﬁc cost and utilization data.
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OBJECTIVES: This prospective, observational, study evaluated
the drug utilization patterns and cost of treatment of patients
treated for rheumatoid arthritis at a government institution
versus a private institution in Kerala, India. METHODS:
Patients with a diagnosis of rheumatoid arthritis were enrolled
into the study and were followed for a period of six months.
Data regarding demographics, clinical outcome, laboratory
results, drug utilizations, and cost was collected. The cost of drug
therapy for each patient was calculated utilizing the Current
Index of Medical Specialties 2004. Nominal data was analyzed
using Chi square and Fisher’s exact test and logistic regression
univariate analysis was conducted to determine the association
between disease improvement and treatment factors. RESULTS:
One hundred thirty-one patients were enrolled in the study, 96
at the government institution and 35 at the private institution.
The mean age was 42.61 and 80% of the patients were female.
The most frequently utilized DMARD was methotrexate, 66%
for the government institution and 80% for the private institu-
tion. The most common DMARD combination therapy was
methotrexate plus hydroxycholoroquine (62.96%). Compliance
was 68.75% in the government patients versus 94.28% in the
private patients (P = 0.003). Logistic regression results indicated
that increased WBC (p = 0.032), ESR (0.003), and COX-2 
usage (p = 0.039) was associated with poorer clinical outcome,
while methotrexate use (p = 0.029) and physiotherapy (p =
0.041) was associated with improved outcome. The clinical
outcome was not signiﬁcantly associated with the site of care.
The average cost of care was Rs. 420.13 per month at the 
government institution versus Rs. 713.14 per month at the
private institution, and 16.1% of the total noncompliance was
due to ﬁnancial constraints. CONCLUSION: The treatment of
rheumatoid arthritis is best managed with a protocol that
includes methotrexate. While ﬁnancial constraints affect the
compliance rate, the site of care did not have any impact on 
clinical outcome.
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OBJECTIVES: Cyclo-oxygenase (COX)-2 inhibitor rofecoxib
and valdecoxib were withdrawn from the market because of
their association with heart problems. There is a lack of infor-
mation on the impacts of COX-2 withdrawal on the utilization
of related drug classes. The objective is to evaluate to what extent
prescriptions and expenditures of non-selective non-steroidal
anti-inﬂammatory drugs (NSAIDs) and proton pump inhibitors
(PPIs) changed after the removal of two COX-2 drugs.
METHODS: Prescription records from January 1, 2004 through
November 30, 2005 were obtained from pharmacy claims data-
base in a pharmacy beneﬁt management (PBM) organization.
Clients continuously enrolled in the PBM but not enrolled in
COX-2, PPI, or Prilosec OTC Step Care programs during the
study period were included. Number of prescriptions per thou-
sand eligible members per month, per member per month
(PMPM) total costs for non-selective NSAIDs and PPIs were cal-
culated and compared between the pre withdrawal (January 1,
2004 through September 30, 2004) and the post withdrawal
(May 1, 2005 through November 30, 2005). RESULTS: This
study included 536,569 patients. After the withdrawal of the two
COX-2 inhibitors, the average non-selective NSAID prescrip-
tions per thousand eligible members per month and PMPM total
costs increased by 37.72% (from 13.94 to 19.20) and 75.56%
(from $0.52 to $0.91). PPI prescriptions and PMPM total costs
increased by 7.21% (from 25.73 to 27.58) and 12.32% (from
$4.38 to $4.92). In contrast, the average prescriptions and
PMPM total costs for COX-2 inhibitors dropped by 70.99%
(from 16.52 to 4.79) and 66.16% (from $2.07 to $0.70). CON-
CLUSIONS: After the withdrawal of COX-2 inhibitor rofecoxib
and valdecoxib, there has been a large increase in non-selective
NSAID prescriptions and only slight increase of PPIs. Given the
safety concerns with the NSAIDs, further studies are warranted
regarding the health outcomes associated with the increased use
of non-selective NSAIDs.
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OBJECTIVES: Different pain thresholds were investigated, using
the WOMAC Pain Scale (WOMAC-P) to determine if they could
differentiate between treatment groups (hylan G-F 20 vs appro-
priate care) at low and very low levels of state-attainment in
patients with knee osteoarthritis. A method, termed the BLISS
(Bellamy et al Low Intensity Symptom State-attainment) Index,
for analyzing Osteoarthritis (OA) knee clinical trials data, was
proposed. METHODS: Five analyses were performed: time to
ﬁrst BLISS day, BLISS days over 12 months, patients with a
BLISS response at month 12, patients with a BLISS response at
any time, and number of BLISS periods over 12 months. For each
analysis, ﬁve levels of WOMAC-P were examined: ≤5 Normal-
ized Units (NU), ≤10, ≤15, ≤20 and ≤25 (higher = more pain).
RESULTS: More patients in the hylan G-F 20 group achieved
BLISS states in all ﬁve analyses. These differences were statisti-
cally signiﬁcant for all pain threshold levels except ≤5NU. CON-
